BCRX

BioCryst Pharmaceuticals Inc

$9.80

0.07 (0.71%) Today

0.06 (0.59%) After-hours

— up— down

Compare BCRX

Market Cap

$2.46B+15.3%

Revenue (TTM)

$901.58M+68.7%

Net Income (TTM)

$-382,256,640

EPS (TTM)

-1.50

Shares Out

254.16M

P/E Ratio

9.56

Open

$9.68

Previous Close

$9.81

Day Range

$9.46 – $9.80

52-Week Range

$6.00 – $11.22

Beta

0.56

Volume

3.69M

Avg Volume

4.63M

Exchange

NASDAQ NMS - GLOBAL MARKET

About BCRX

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.